Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell Lymphoma : Episode 2

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31, 2023

Kami J. Maddocks, MD
Alexey V. Danilov, MD, PhD

Video

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

EP: 1.Overview of Mantle Cell Lymphoma

EP: 2.Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

EP: 3.Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

EP: 4.Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

EP: 5.Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

EP: 6.Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

EP: 7.Future Directions in the Treatment of Mantle Cell Lymphoma

Related Videos

Experts on FL

Expert on FL

Expert on SCLC

Experts on myelodysplastic syndrome

Experts on myelodysplastic syndrome

Tycel Phillips, MD, MPH

Tycel Phillips, MD, MPH

Experts on GVHD

Related Content

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14th 2023

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma

August 21st 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Pirtobrutinib Demonstrates Durable Efficacy in Pretreated Mantle Cell Lymphoma

August 6th 2023

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14th 2023

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma

August 21st 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Pirtobrutinib Demonstrates Durable Efficacy in Pretreated Mantle Cell Lymphoma

August 6th 2023

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14th 2023

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma

August 21st 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Pirtobrutinib Demonstrates Durable Efficacy in Pretreated Mantle Cell Lymphoma

August 6th 2023

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Related Content

Brad S. Kahl, MD

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14th 2023

Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Monica D. Mead, MD

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma

August 21st 2023

Joshua Brody, MD

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Nirav Shah, MD, discusses the efficacy of pirtobrutinib in patients with mantle cell lymphoma who were previously treated with a covalent BTK inhibitor and progressed, and outlines the next steps for exploration of the noncovalent BTK inhibitor in this population.

Pirtobrutinib Demonstrates Durable Efficacy in Pretreated Mantle Cell Lymphoma

August 6th 2023

Swetha Kambhampati, MD

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.